This week's top stories: drug candidates with blockbuster potential for CNS diseases & initial in vivo validation of novel cancer therapeutic using AI

This week's top stories: drug candidates with blockbuster potential for CNS diseases & initial in vivo validation of novel cancer therapeutic using AI

?? Trending news from the industry

? Initial in vivo validation of novel cancer therapeutics using AI

In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. Read more >>>

? Drug candidates with blockbuster potential for CNS diseases

In this Q&A, Kristina Torfg?rd, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future. Read more >>>

? Overcoming operational challenges in CGT manufacturing with AI

In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing AI solutions. Read more >>>

? Women in Stem with María Perelló

We spoke to María Perelló, Medical Director at the Oncology Business Unit at Daiichi Sankyo Spain. As a gynaecologist, with a PhD in Endometriosis and an Executive MBA, she has many years of experience in the pharma industry as Medical Advisor, Medical Manager and Therapeutical Area Manager. Read more >>>

? Damaged small intestine repaired with hPSC-derived organoids

Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials. Read more >>>

?? Webinar of the week

Join our upcoming webinar to explore the complexities of producing and characterizing challenging recombinant proteins like GPCRs. We'll dive into how cutting-edge biophysical methods are transforming GPCR hit finding and hit confirmation.

Whether you're in drug discovery or biophysics, this session is packed with insights to enhance your research and development efforts.

?? Reserve your seat today!

?? Listen up!

??? New Podcast: Transforming Toxicity Testing

Explore how innovative assays and human-relevant cell models are reshaping toxicity screening in drug development.

Join Professor Ruth Roberts (ApconiX) and Dr. Oksana Sirenko (Molecular Devices) for insights into advanced toxicity testing methods.

?? Listen here

??? Sign up for free!

Sign up here to stay ahead of all the latest breaking news, expert insights and the newest trends in global drug discovery.

Drug Target Review is an essential multimedia resource which is trusted and recognised globally of researchers and scientific leaders who cover the most up-to-date innovations, and cutting edge technologies in the industry.


要查看或添加评论,请登录